FORT LEE, N.J.--(EON: Enhanced Online News)--KEDPLASMA USA, one of the world’s leading collectors of high-quality human blood plasma, has announced the acquisition of two additional plasma collection centers from ImmunoTek Bio Centers, LLC, effective on April 1, 2017. KEDPLASMA USA’s acquisition of the two plasma collection centers, which are located in Kissimmee, Florida, and Burlington, North Carolina, is another step forward in a five-year strategic plan to double the number of centers the Company operates so that more patients may have access to the therapies offered by Kedrion Biopharma.
“It is always exciting to welcome new personnel and donors to the KEDPLASMA USA family.”
KEDPLASMA USA collects plasma for Kedrion Biopharma Inc., which, in turn, uses it in the production of safe, effective, plasma-derived therapies that treat a range of rare and serious health conditions, including hemophilia, immunological and neurological conditions, and certain acute, life-threatening conditions requiring treatment in the critical care setting.
KEDPLASMA USA is also one of the largest suppliers of high rabies antibody titer plasma in the world. Its parent company, Kedrion Biopharma Inc., is a subsidiary of Kedrion S.p.A. (Kedrion Biopharma).
“With the addition of these two centers, along with the ongoing expansion that KEDPLASMA USA is undergoing, we continue to expand our capability to meet the increasing requirements of our parent company, Kedrion Biopharma. This allows the Company to manufacture and distribute the critical therapies so needed by patients who have certain rare and serious health conditions,” said Helen Nasser, KEDPLASMA USA Managing Director. “It is always exciting to welcome new personnel and donors to the KEDPLASMA USA family.”
All centers owned and operated by KEDPLASMA USA are licensed and regulated by the U.S. Food and Drug Administration and are approved and monitored by the relevant European healthcare regulation authorities.
ImmunoTek Bio Centers, LLC CEO and President, Jerome Parnell III, said, “The transition of these assets to KEDPLASMA USA represents ImmunoTek’s ability to provide maximum flexibility to all of our customers as they seek to fulfill their strategic plasma supply needs. It also further enhances our relationship with Kedrion Biopharma, a strong partner in the global biopharma market.”
About KEDPLASMA and Kedrion Biopharma
KEDPLASMA LLC. was established in 2004 and is a subsidiary of Kedrion Biopharma Inc., the U.S. subsidiary of Kedrion S.p.A.. Kedrion Biopharma Inc. and KEDPLASMA LLC. are both headquartered in the United States. KEDPLASMA collects high quality human blood plasma, the vital raw material that allows Kedrion Biopharma to produce and distribute plasma-derived therapeutic products for use in treating and/or preventing serious diseases and conditions such as hemophilia, primary immune system deficiencies and Rh sensitization which can lead to hemolytic disease of the fetus and newborn.
Headquartered in Tuscany, Italy, Kedrion Biopharma has a market presence in approximately 100 countries. It ranks fifth in terms of annual revenues in the global plasma derivatives market. Its largest and fastest growing market is the United States, with U.S. headquarters in Fort Lee, NJ. Italy is its next most important market, followed by Turkey, Mexico and Russia. In 2015, Kedrion Biopharma reached more than 570.3 million euros (more than $621 MM USD) in gross revenues. Nearly $275 million of that sum was generated in the U.S. The company employs over 2,240 people worldwide.
Kedrion Biopharma acts as a vital bridge connecting donors and patients. We operate on a global scale with the aim of expanding patients’ access to available treatments. Kedrion Biopharma places a high value on the welfare of those who benefit from its products and on the people and communities where it operates.
Following a vertically-integrated business model, Kedrion Biopharma manages the entire plasma cycle from supply and therapy production to distribution. In Italy, Kedrion Biopharma is a partner of the National Health Service and collaborates in pursuing self-sufficiency in the development and supply of plasma-derived medicinal products. The Company’s goal is to foster self-sufficiency in plasma-derived therapies worldwide and to bring healthier lives to people everywhere who suffer from rare disorders.
Kedrion Biopharma has six production plants: Three in Italy (a new plant in Castelvecchio Pascoli, now nearing completion, and one in Bolognana, both in the province of Lucca, and one in Sant’Antimo, Naples); one in Hungary (Gödöllő, Budapest); and one in the United States (Melville, NY). A facility in Siena, Tuscany, specializes in research and development of orphan drugs.
KEDPLASMA operates collection centers in the United States. Its sister companies in Europe operate centers in Germany and Hungary. All centers have been granted approval and licensure by European healthcare authorities and/or the U.S. Food and Drug Administration and are managed in strict compliance with all regulations. KEDPLASMA is also one of the world’s leading suppliers of high-titer rabies plasma. The center in Buffalo, New York, specializes in collecting hyper-immune Anti-D human plasma for the manufacture of an Anti-D immunoglobulin pharmaceutical product. State-of-the-art production facilities producing a wide range of products and an unwavering commitment to research and development are the key factors in Kedrion Biopharma’s success.
About ImmunoTek Bio Centers LLC
ImmunoTek BioCenters is an emerging bio-tech company committed to the safe collection and procurement of human blood plasma from the public. The management team has extensive experience in the blood, plasma, and biopharma industries. Through contracts and strategic agreements with pharmaceutical companies, IMMUNOTEK is fully capable of constructing, opening, FDA/EU licensing, and managing multiple plasma collection sites and plasma supply contracts in order to meet on going demand in the plasma proteins therapeutics market. Growth of current therapeutic drugs and vaccines as well as additional new therapeutic indications expected to put considerable strain on global blood plasma supply. IMMUNOTEK currently owns and operates plasma collection centers in the USA and has over 40 collection centers in development through 2020.